Reata Pharmaceuticals Inc (NASDAQ:RETA)

27.89
Delayed Data
As of 4:00pm ET
 +0.29 / +1.05%
Today’s Change
25.02
Today|||52-Week Range
153.41
+5.76%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$1.0B

Company Description

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by W. Christian Wigley, Waldemar Priebe, Philip J. Thomas, Jef Karel de Brabander, Thomas C. Sudhof, Jonathan M. Graff, and J. Warren Huff in 2002 and is headquartered in Irving, TX.

Contact Information

Reata Pharmaceuticals, Inc.
5320 Legacy Drive
Plano Texas 75024
P:(972) 865-2219
Investor Relations:
(469) 299-9130

Employees

Shareholders

Mutual fund holders54.95%
Other institutional28.39%
Individual stakeholders23.84%

Top Executives

J. Warren HuffChairman, President & Chief Executive Officer
Manmeet Singh SoniExecutive VP, Chief Operating & Financial Officer
W. Christian WigleyChief Scientific Officer, SVP & Founding Scientist
Colin J. MeyerChief Research & Development Officer, Executive VP
Edmund DohertyVice President-Medical Affairs